A Phase I Dose-escalation Study of LBH589 Administered Orally in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma

Inclusion Criteria:

- Patients with either a) histologically-confirmed, advanced solid tumors whose disease
has progressed despite standard therapy or for whom no standard therapy exists, or b)
cytopathologically confirmed cutaneous T-cell lymphoma (CTCL) whose disease has
progressed despite standard therapy or for whom no standard therapy exists. Inclusion
is irrespective of stage of disease or extent of prior therapy.

- World Health Organization (WHO) Performance Status of ≤ 2

- Patients must have the adequate laboratory values

Exclusion Criteria:

- Patients with a history of primary CNS tumors

- Patients with any history of brain metastases

- Patients with any peripheral neuropathy ≥ CTCAE grade 2

- Patients with unresolved diarrhea ≥ CTCAE grade 2

- Impairment of cardiac function

- Impairment of gastrointestinal (GI) function or GI disease

- Liver or renal disease

Other protocol-defined inclusion/exclusion criteria may apply